We have explored the use of our Aganocide compounds in multiple indications, including dermatology, ophthalmology, and urology; the last being identified as the one with the most promise. Statistically-significant and clinically-meaningful results from a Phase 2 clinical study of our Auriclosene Irrigation Solution (AIS) used to reduce urinary catheter blockage and encrustation (UCBE), were announced in September 2013. This study, comparing AIS to saline solution, achieved its primary endpoints and showed clear benefit to patients with long-term indwelling catheters. We initiated the next Phase 2 study in the fourth quarter of 2014 and in the fourth quarter of 2015, we announced completion of that study. Patients with long-term indwelling urinary catheters were treated with AIS or its Vehicle. The results of this more demanding study showed that AIS was better than its vehicle in preventing the reduction of flow through catheters due to encrustation (the primary efficacy measure) by a statistically-significant margin. Furthermore, there were no cases of clinical catheter blockage in the AIS arm of the study; all cases of clinical blockage requiring catheter removal occurred only in the Vehicle arm.
We are very excited about our urology program, and believe this has the potential for greatly improving the lives of many permanently catheterized people. We are actively seeking partnerships to aid us in accomplishing our goal of fulfilling this unmet patient need.
If you are interested in exploring the possibilities of a strategic partnership with NovaBay, please contact:
The Office of Business Development